Introduction
Subjects and methods
Study design and participants
Questionnaire
BREAST-Q scale
Statistical analysis
Results
Characteristics of the participants
Characteristic | n (%) | Satisfactory degree score | P | HRQOL | P |
---|---|---|---|---|---|
Total score | 206.5±18.6 | 73.6±10.6 | |||
Age | <0.001 | <0.001 | |||
≤ 35 years | 65 (32.2) | 214.3±13.9 | 78.2±11.4 | ||
36–45 years | 84 (41.6) | 207.1±18.9 | 73.6±9.4 | ||
> 45 years | 53 (26.2) | 196.1±18.3 | 67.9±8.7 | ||
Educational level | 0.190 | 0.098 | |||
Primary school or junior middle school | 38 (18.8) | 203.0±18.0 | 71.0±11.5 | ||
Senior middle school or higher | 164 (81.2) | 207.3±18.6 | 74.2±10.3 | ||
Marital status | 0.117 | 0.203 | |||
Married | 19 3 (95.5) | 206.1±18.7 | 73.4±10.7 | ||
Unmarried | 9 (4.5) | 216.0±12.5 | 78.00±7.3 | ||
Residence | 0.436 | 0.249 | |||
Towns or cities | 116 (57.4) | 207.4±20.3 | 74.34±10.9 | ||
Rural area | 86 (42.6) | 205.3±15.9 | 72.59±10.1 | ||
Body mass index | 0.001 | 0.498 | |||
< 18.5 kg/m2 | 5 (2.5) | 215.8±6.7 | 79.00±14.3 | ||
18.5–24 kg/m2 | 143 (70.8) | 209.3±16.3 | 73.58±9.9 | ||
> 24 kg/m2 | 54 (26.7) | 198.4±22.2 | 73.13±12.0 | ||
TNM stage | <0.001 | 0.012 | |||
0–I | 77 (38.1) | 211.3±14.3 | 71.12±11.5 | ||
II | 109 (54.0) | 205.3±19.8 | 74.61±10.2 | ||
III–IV | 16 (7.9) | 191.7±20.1 | 78.56±5.1 | ||
Radiotherapy | <0.001 | <0.001 | |||
Yes | 51 (25.2) | 196.0±19.1 | 78.5±7.2 | ||
No | 151 (74.8) | 210.1±17.0 | 71.9±11.1 | ||
Chemotherapy | <0.001 | 0.416 | |||
Yes | 125 (61.9) | 202.9±19.8 | 74.1±10.3 | ||
No | 77 (38.1) | 212.3±14.7 | 72.8±11.1 | ||
Endocrine therapy | 0.579 | 0.425 | |||
Yes | 135 (66.8) | 207.0±16.8 | 74.0±10.0 | ||
No | 67 (33.2) | 205.5±21.7 | 72.8±11.7 | ||
Neoadjuvant chemotherapy | 0.001 | <0.001 | |||
Yes | 47 (23.3) | 198.4±20.4 | 78.5±9.3 | ||
No | 155 (76.7) | 209.0±17.3 | 72.1±10.6 | ||
Surgical approach | 0.027 | 0.034 | |||
Anterior pectoralis approach | 10 (5.0) | 193.9±15.8 | 80.5±6.4 | ||
Posterior pectoralis approach | 192 (95.0) | 207.2±18.5 | 73.2±10.7 | ||
Surgical mode | 0.133 | <0.001 | |||
NSM/ssm+ sentinel lymph node dissection + prosthesis implantation | 128 (63.4) | 208.5±16.8 | 72.5±10.4 | ||
NSM/ssm+ axillary lymph node dissection + prosthesis implantation | 35 (17.3) | 202.6±25.2 | 78.4±9.5 | ||
NSM/ssm+ sentinel lymph node dissection + prosthesis implantation + contralateral breast augmentation | 22 (10.9) | 207.7±15.9 | 67.2±11.0 | ||
Latissimus dorsi flap | 5 (2.5) | 204.0±22.6 | 78.8±7.4 | ||
Transverse rectus abdominis myocutaneous flap | 12 (5.9) | 195.9±13.0 | 81.1±6.3 | ||
Breast volume | 0.166 | 0.940 | |||
≤ 200 mL | 82 (40.6) | 208.8±16.6 | 73.3±9.6 | ||
201–300 mL | 102 (50.5) | 205.8±20.2 | 73.8±11.6 | ||
> 300 mL | 18 (8.9) | 200.1±16.1 | 73.7±9.3 | ||
Length of scar | 0.116 | 0.019 | |||
>20 cm | 185 (91.6) | 207.3±18.6 | 73.0±10.7 | ||
10–20 cm | 5 (2.5) | 204.0±22.6 | 78.8±7.4 | ||
<10 cm | 12 (5.9) | 195.9±13.0 | 81.1±6.3 | ||
Time of breast reconstruction | 0.814 | 0.549 | |||
≤ 1 year | 48 (23.8) | 207.1±15.9 | 72.8±10.9 | ||
2–3 years | 154 (76.2) | 206.3±19.3 | 73.8±10.5 | ||
Timing of reconstruction | 0.277 | 0.261 | |||
Immediate reconstruction | 198 (98.0) | 206.7±18.6 | 73.5±10.6 | ||
2-phase reconstruction | 4 (2.0) | 196.5±10.3 | 79.5±6.6 | ||
Flap harvesting | 0.068 | 0.014 | |||
Yes | 16 (7.9) | 198.6±16.5 | 79.9±6.3 | ||
No | 185 (91.6) | 207.4±18.5 | 73.1±10.7 | ||
Use of SIS matrix | 0.128 | 0.004 | |||
Yes | 4 (2.0) | 220.5±8.2 | 88.8±5.9 | ||
No | 198 (98.0) | 206.2±18.6 | 73.3±10.5 |
Multivariable analysis of satisfaction degree and HRQOL
Variable | Regression coefficient (B) | Standardized regression coefficient (β) | P |
---|---|---|---|
Age | |||
≤ 35 years | Ref | ||
36–45 years | − 4.694 | − 0.125 | 0.086 |
> 45 years | − 15.746 | − 3.74 | <0.001 |
Body mass index | |||
< 18.5 kg/m2 | Ref | ||
18.5–24 kg/m2 | − 3.129 | − 0.077 | 0.676 |
> 24 kg/m2 | − 8.633 | − 0.206 | 0.266 |
TNM stage | |||
0–I | Ref | ||
II | − 1.273 | − 0.034 | 0.644 |
III–IV | − 9.261 | − 0.135 | 0.097 |
Radiotherapy | − 8.589 | − 0.202 | 0.062 |
Chemotherapy | − 4.759 | − 0.125 | 0.084 |
Neoadjuvant chemotherapy | 2.742 | 0.063 | 0.538 |
Surgical approach | |||
Anterior pectoralis approach | Ref | ||
Posterior pectoralis approach | 1.999 | 0.023 | 0.722 |
Variable | Regression coefficient (B) | Standardized regression coefficient (β) | P |
---|---|---|---|
Age | |||
≤ 35 years | Ref | ||
36–45 years | − 5.611 | − 0.262 | <0.001 |
>45 years | − 10.796 | − 0.451 | <0.001 |
TNM stage | |||
0–I | Ref | ||
II | 6.75 | 0.032 | 0.657 |
III–IV | − 2.300 | − 0.059 | 0.487 |
Chemotherapy | 4.544 | 1.87 | 0.090 |
Neoadjuvant chemotherapy | 0.548 | 0.022 | 0.840 |
Surgical approach | |||
Anterior pectoralis approach | Ref | ||
Posterior pectoralis approach | 1.666 | 0.034 | 0.740 |
Surgical mode | |||
NSM/SSM+ sentinel lymph node dissection + prosthesis implantation | Ref | ||
NSM/SSM+ axillary lymph node dissection + prosthesis implantation | 1.590 | 0.057 | 0.480 |
NSM/SSM+ sentinel lymph node dissection + prosthesis implantation + contralateral breast augmentation | − 5.441 | − 0.161 | 0.012 |
Latissimus dorsi flap | 13.540 | 0.200 | 0.228 |
Transverse rectus abdominis myocutaneous flap | 15.390 | 0.346 | 0.118 |
Flap harvesting | − 7.851 | − 0.201 | 0.461 |
Use of SIS matrix | 9.635 | 0.128 | 0.044 |